Why the study?
What are the patterns and predictors of quadruple evidence-based medication use at discharge in patients with acute coronary syndrome?
What are the patterns and predictors of quadruple evidence-based medication use at discharge in patients with acute coronary syndrome?
Guideline adherence to the concurrent use of quadruple evidence-based medications at discharge in ACS patients in the Middle East is suboptimal at 49%.
Answers are grounded in this paper and cite their sources.
Suboptimal quadruple EBM use at ACS discharge signals care gaps; leaves open predictors and targeted strategies in Middle Eastern cohorts.
We evaluated the use of quadruple evidence-based medication (EBM) combination consisting of antiplatelet therapy, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, β-blocker, and lipid-lowering agent concurrently at discharge among patients (n = 8154) with acute coronary syndrome (ACS) in 6 Middle Eastern countries. In all, 49% of the patients received the quadruple EBM combination concurrently at discharge. An adjusted model demonstrated that old age, diabetes mellitus, hyperlipidemia, hypertension, ST-segment elevation myocardial infarction, cardiac catheterization, as well as cardiologists as care providers and hospitals with cardiac catheterization facilities were all positively correlated with the use of the quadruple EBM combination. However, patients with cardiogenic shock, renal impairment, higher risk score, congestive heart failure, recurrent ischemia, and those admitted to academic hospitals were negatively correlated with the use of the quadruple EBM combination. Guideline adherence to the concurrent use of quadruple EBM combination in patients with ACS at discharge was suboptimal with wide disparity among the 6 countries.
No takes yet. Share an insight, caveat, or question.
Al‐Zakwani et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: